MET and NF2 alterations confer primary and early resistance to first‐line alectinib treatment in ALK ‐positive non‐small‐cell lung cancer
Molecular Oncology · 2025-09 · 19 (9) · 2715-2729
DOI: 10.1002/1878-0261.70029 ↗Kurz gefasst
Fachartikel in der Zeitschrift Molecular Oncology, 2025-04. Verfasst von Jie Hu und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pulmonary Medicine, Shanghai Geriatric Medical Center, China. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Carbazoles, Lung Neoplasms, Piperidines. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 63 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Science and Technology Commission of Shanghai Municipality, National Key R&D Plan, Shanghai Municipal Key Clinical Specialty.
Abstract (Originalsprache)
Although first‐line alectinib has prolonged survival in ALK‐ mutated non‐small‐cell lung cancers (NSCLCs), the response to treatment varies among patients, and the primary/early development of alectinib resistance mechanisms is still not fully understood. Here, we analyzed molecular profiles of 108 alectinib‐treated patients (first‐line and second‐line after crizotinib) with confirmed relapse by targeted sequencing of cancer‐related genes. After first‐line treatment, off‐target MET and NF2 alterations were more frequent than on‐target alterations within the first 6 months, causing primary or early resistance. Conversely, on‐target alterations became prevalent after 1 year of first‐line alectinib treatment and predominantly after second‐line. The incidence of acquired resistance also depended on EML4‐ALK variants. In variant 1 (v1), off‐target alterations were responsible for 50% of resistance cases after first‐line alectinib therapy, whereas on‐target mutations had no contribution in this subgroup. In variant 3 (v3), on‐target alterations resulted in 46% of resistance cases, whereas only 18% were caused by off‐target mutations. After second‐line treatment, the most common mutations in v1 were L1196M (42%) and G1269A (25%), while G1202R was detected in 45% of v3 tumors. These findings emphasize the importance of stratifying resistance mechanisms to guide tailored treatment for ALK ‐positive NSCLCs.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pulmonary Medicine, Shanghai Geriatric Medical Center, China.
- Department of Pulmonary Medicine, Zhongshan Hospital, Fudan University, Shanghai, China.
- Shanghai Respiratory Research Institute, China.
- Geneseeq Research Institute, Nanjing Geneseeq Technology Inc., China.
- School of Public Health, Nanjing Medical University, China.
- Shanghai Key Laboratory of Lung Inflammation and Injury, Department of Pulmonary Medicine, Zhongshan Hospital, Fudan University, Shanghai, China.
ORCID-Profile: Jie Hu, Yedan Chen
Förderung
- Science and Technology Commission of Shanghai Municipality
- National Key R&D Plan
- Shanghai Municipal Key Clinical Specialty
- National Natural Science Foundation of China
- Shanghai Municipal Science and Technology Major Project, Clinical Research Plan of SHDC
Zitieren
APA
Hu, J., Ding, N., Xu, X., Chen, Y., Zhang, Y., Liu, J., Zhou, J., Bao, H., Zhang, D., Song, Y., Shao, Y., & Song, Y. (2025). MET and NF2 alterations confer primary and early resistance to first‐line alectinib treatment in ALK ‐positive non‐small‐cell lung cancer. Molecular Oncology, 19(9), 2715-2729. https://doi.org/10.1002/1878-0261.70029
Vancouver
Hu J, Ding N, Xu X, Chen Y, Zhang Y, Liu J, et al. MET and NF2 alterations confer primary and early resistance to first‐line alectinib treatment in ALK ‐positive non‐small‐cell lung cancer. Molecular Oncology. 2025;19(9):2715-2729. doi:10.1002/1878-0261.70029
BibTeX
@article{Hu2025,
author = {Hu, Jie and Ding, Ning and Xu, Xiaobo and Chen, Yedan and Zhang, Yong and Liu, Jingwen and Zhou, Jiebai and Bao, Hairong and Zhang, Donghui and Song, Yijun and Shao, Yang and Song, Yuanlin},
title = {MET and NF2 alterations confer primary and early resistance to first‐line alectinib treatment in ALK ‐positive non‐small‐cell lung cancer},
journal = {Molecular Oncology},
year = {2025},
volume = {19},
number = {9},
pages = {2715--2729},
doi = {10.1002/1878-0261.70029}
}
EUVIMED